Azienda Unita' Locale Socio Sanitaria N. 2 Marca Trevigiana

Research site

Italy Via Brigata Bisagno 4, 31015 Conegliano, Italy

Pulmonary embolism · Venous thrombosis · Type 2 diabetes mellitus
Adult patients

About Specializations

Azienda Unita' Locale Socio Sanitaria N. 2 Marca Trevigiana in Conegliano, Italy specialises in clinical trials of conditions such as Pulmonary embolism, Venous thrombosis, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Via Brigata Bisagno 431015 ConeglianoItaly

Open in maps ↗

Recruiting now: no trials
Conditions studied: 3

More sites in Conegliano Italy

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

2 clinical trials

Pulmonary embolism+1

Not yet recruiting

Study on Sulodexide for Preventing Recurrence of Blood Clots in Elderly Patients After First Episode of Deep Vein Thrombosis or Pulmonary Embolism

Registered drug

Study on Sulodexide for Preventing Recurrence of Blood Clots in Elderly Patients After First Episode of Deep Vein Thrombosis or Pulmonary Embolism

Registered drug

Italy

Participants:65+ years
Substances:Sulodexide
Sponsor:Fondazione Arianna Anticoagulazione

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of Metformin Hydrochloride, Dapagliflozin, and Canagliflozin in Elderly Patients with Type 2 Diabetes

Registered drugNo placebo

Study on the Safety and Effectiveness of Metformin Hydrochloride, Dapagliflozin, and Canagliflozin in Elderly Patients with Type 2 Diabetes

Registered drugNo placebo

Italy

Participants:65+ years
Substances:Canagliflozin
Sponsor:Center For Outcomes Research And Clinical Epidemiology S.r.l.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites